Genetic Basis of Melanocytic Nevi
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Collecting Nevi.
- Who it may be relevant to
- Registry conditions: Melanocytic Nevi. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The objective of this protocol is to further elucidate the genetic mutations that drive melanocytic nevi (benign melanocytic neoplasms, moles). This will be performed by whole genome, whole exome, or targeted sequencing of de-identified specimens. Herein, the investigators plan to isolate DNA from de-identified skin biopsy specimens and blood samples: 1. From melanocytic nevi collected by skin biopsy (a shave or punch biopsy). A part of the tissue will be submitted for routine diagnostic dermatopathology and investigational histomorphologic and immunohistochemical analysis. 2. From corresponding normal tissue (blood). DNA isolated from blood will be used as a normal control when analyzing sequencing data to identify somatic mutations in lesional tissue.
Interventions
- Other Collecting Nevi
Will be collecting Nevi and completing a DNA analysis, no intervention will be made.
Primary outcome measures
- Genome Wide Mutation Analysis [Time frame: Feb 2017 - December 2018]
Eligibility criteria
Inclusion criteria
- Male or female subjects that are 18 years or older
- Subjects with melanocytic nevi\\
Exclusion criteria
- Patients less than 18 years of age
- Patients without melanocytic nevi
- Patients with a bleeding disorder or are taking anticoagulation medication
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
United States · 1 center
- University of California-Davis, Department of Dermatology — Sacramento
Identifiers
NCT: NCT03054584 · 960347